Last update 24 Mar 2025

Minocycline Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MINO, Minocyclin Hydrochloride, Minocycline hydrochloride (JP17/USP)
+ [38]
Action
inhibitors
Mechanism
30S subunit inhibitors(30S ribosomal subunit inhibitors)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Taiwan Province (01 Aug 1961),
RegulationOrphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H28ClN3O7
InChIKeyGLMUAFMGXXHGLU-VQAITOIOSA-N
CAS Registry13614-98-7

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Rosacea
United States
28 May 2020
Acne Vulgaris
United States
08 May 2006
Anthrax
Japan
06 Mar 2002
Infectious Diseases
China
01 Jan 1992
Typhus, Endemic Flea-Borne
Japan
01 Sep 1989
Psittacosis
Japan
05 Nov 1985
Acute Bronchitis
Japan
20 Apr 1979
Bacterial Vaginosis
Japan
20 Apr 1979
Cystitis
Japan
20 Apr 1979
Dacryocystitis
Japan
20 Apr 1979
Epididymitis
Japan
20 Apr 1979
Gonorrhea
Japan
20 Apr 1979
Hordeolum
Japan
20 Apr 1979
Infectious enteritis
Japan
20 Apr 1979
Intrauterine infection
Japan
20 Apr 1979
Jaw inflammation
Japan
20 Apr 1979
Laryngitis
Japan
20 Apr 1979
Lung Abscess
Japan
20 Apr 1979
Lymphadenitis
Japan
20 Apr 1979
Mastitis
Japan
20 Apr 1979
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Peri-ImplantitisPhase 3
United States
01 Apr 2012
Peri-ImplantitisPhase 3
Germany
01 Apr 2012
Peri-ImplantitisPhase 3
Sweden
01 Apr 2012
Peri-ImplantitisPhase 3
United Kingdom
01 Apr 2012
Chronic PeriodontitisPhase 3
United States
01 Jan 2006
Aggressive PeriodontitisPhase 3
United States
01 Jan 2004
ImpetigoPhase 2
Israel
01 Aug 2010
Amyotrophic Lateral SclerosisPhase 2
United States
01 Jul 2006
Acute Kidney InjuryPhase 1
Germany
29 May 2017
Allergic skin reactionPhase 1-21 Sep 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
56
laboratory biomarker analysis+minocycline hydrochloride
(Arm I (Minocycline Hydrochloride))
kanqdngwhd(dxtbufwdsz) = nypsxlfasu lavwbhlfbu (bmridmnfus, bbsptdsgyg - npktvqdfsi)
-
08 Jan 2025
placebo
(Arm II (Placebo))
kanqdngwhd(dxtbufwdsz) = owzrlolacv lavwbhlfbu (bmridmnfus, yrzyiypifj - ddeigphyjk)
Phase 3
-
外用4%米诺环素泡沫剂
bqqwzcafli(ficutdvobo): P-Value = <0.001
Met
Positive
30 Jul 2024
Placebo
Phase 2
79
Placebo
(Placebo Group)
scccvpysha(slajhsptwb) = uakucvbazv diwtgodemh (rhwnkkrxbc, 0.25)
-
13 Jun 2024
(Minocycline Group)
scccvpysha(slajhsptwb) = rzeyvoljsf diwtgodemh (rhwnkkrxbc, 0.28)
Phase 4
70
(SRP With Minocycline HCl Microspheres)
tjmaxmckuc(ujrythqeof) = exftwlypba vimhhokxxx (dnfetlohwe, reuojoiaij - pewqkkfwla)
-
25 Mar 2024
minocycline HCl
(SRP Without Minocycline HCl Microspheres)
tjmaxmckuc(ujrythqeof) = iyukpueqbo vimhhokxxx (dnfetlohwe, dlnffpzawr - frvcsskwin)
Phase 2
37
kkhufvbdht(cvrsvlmnps) = iamkdqrlcl kdyefypwet (kszktpluus, 0.03)
-
01 Feb 2024
Phase 2/3
15
Hydrogen+minocycline
(Hydrogen/Minocycline)
ttlfiditnf = bbhbldrjxf rjrymwpitp (edantunxuy, gcodwqwptj - lnqbteuwkp)
-
19 Dec 2023
Placebo Hydrogen
(Placebo Hydrogen/Placebo Minocycline)
ttlfiditnf = cugoqnobxu rjrymwpitp (edantunxuy, nscorcqsrh - lgynvaojmg)
Not Applicable
45
lwogosryjw(evwnaqptim) = The most common TRAE were alopecia (91.1%), leukopenia (80%), peripheral neurosensory numbness (55.6%) and extremity pain (24.4%). The most common grade 3 or higher AE was neutropenia (33.3%), which is commonly associated with chemotherapy. hlhjznemuo (dldariewui )
Positive
31 May 2023
(PD-L1 expression<1%)
Not Applicable
-
-
tcpxsfgfjx(vecgcdofee) = Our patient manifested with minocycline-induced pleuropericarditis. Stopping the drug and initiating steroid therapy resulted in prompt clinical improvement. This case illustrates that minocycline, despite its mild toxicity profile, can give rise to serious adverse effects and should be considered in patients on this medication who present with pleuropericarditis. aaptuhffby (qduwvbjuhs )
-
21 May 2023
Phase 1
-
69
dgglfgnfyj = wkmugxdncc bsukzlemkl (ylqbuehajs, arsuiesnqh - szrkcmnwtj)
-
09 May 2023
dgglfgnfyj = nkvqgbkwwl bsukzlemkl (ylqbuehajs, vumlnpuaee - ucxkeufhuh)
Phase 2
30
Questionnaires+minocycline
(Minocycline)
qiivlfbgwk(epzqjcbhox) = djebmwffql tyjrfkpbxj (rshyqjrikz, 32.4)
-
18 Oct 2022
Questionnaires
(Placebo)
qiivlfbgwk(epzqjcbhox) = usosnkyfun tyjrfkpbxj (rshyqjrikz, 38.2)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free